Join 100+ Experts Including:
13th World Bispecific Summit: The Only End-to-End Meeting Committed Solely to Advancing the Development of Bi- & Multi-Specific Therapeutics
With more clinical candidates and commercial success than ever within this rapidly developing space, multi-specifics is evidently the fourth wave of drug discovery. With this, there has never been a hotter time to double down and deliver the holy grail of precision oncology as the true power of bispecifics is recognized.
The 13th Annual World Bispecific Summit will deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover unique target discovery, mechanistic diversity and translational science as well as novel formats, product design and manufacturability challenges faced in the bispecific field.
Whatever your role or interest, you will leave the meeting with concrete methods to employ in your strategy and pipeline to convert the promise of bi- and multi-specific therapeutics into a reality for patients.
With 2 tracks of unrivaled content, join with your team to catapult this community into the next generation of translational success, clinical progress, advanced mechanistic diversity, reduced toxicity and higher target affinity. Utilize the pre-conference focus day dedicated to Novel Formats and Immune Cell Modulators of multispecifics to further drive your clinical and antibody engineering strategies forward.
Among Our World-Class Speaker Faculty



Chava Kimchi-Sarfaty
Deputy Associate Director - Research Office of Tissue & Advanced Therapies
CBER, FDA


